Literature DB >> 19789068

Postherpetic neuralgia: from preclinical models to the clinic.

Ada Delaney1, Lesley A Colvin, Marie T Fallon, Robert G Dalziel, Rory Mitchell, Susan M Fleetwood-Walker.   

Abstract

Postherpetic neuralgia (PHN), a common complication of herpes zoster, which results from reactivation of varicella zoster virus, is a challenging neuropathic pain syndrome. The incidence and severity of herpes zoster and PHN increases with immune impairment or age and may become a greater burden both in terms of health economics and individual suffering. A clearer understanding of the underlying mechanisms of this disease and translation of preclinical outcomes to the clinic may lead to more efficacious treatment options. Here we give an overview of recent findings from preclinical models and clinical research on PHN.

Entities:  

Mesh:

Year:  2009        PMID: 19789068      PMCID: PMC5084285          DOI: 10.1016/j.nurt.2009.07.005

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  118 in total

Review 1.  Sodium channels and the molecular pathophysiology of pain.

Authors:  T R Cummins; S D Dib-Hajj; J A Black; S G Waxman
Journal:  Prog Brain Res       Date:  2000       Impact factor: 2.453

2.  Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury.

Authors:  R A Newton; S Bingham; P C Case; G J Sanger; S N Lawson
Journal:  Brain Res Mol Brain Res       Date:  2001-11-01

3.  The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.

Authors:  J C Hunter; K R Gogas; L R Hedley; L O Jacobson; L Kassotakis; J Thompson; D J Fontana
Journal:  Eur J Pharmacol       Date:  1997-04-18       Impact factor: 4.432

4.  A double-blind, placebo-controlled study of oral acyclovir in postherpetic neuralgia.

Authors:  O S Surman; T Flynn; R T Schooley; L Baer; S Parker; M S Hirsch; L G Davis
Journal:  Psychosomatics       Date:  1990       Impact factor: 2.386

5.  Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts.

Authors:  Stefan L Oliver; Leigh Zerboni; Marvin Sommer; Jaya Rajamani; Ann M Arvin
Journal:  J Virol Methods       Date:  2008-09-24       Impact factor: 2.014

6.  EFNS guidelines on neuropathic pain assessment.

Authors:  G Cruccu; P Anand; N Attal; L Garcia-Larrea; M Haanpää; E Jørum; J Serra; T S Jensen
Journal:  Eur J Neurol       Date:  2004-03       Impact factor: 6.089

Review 7.  Varicella zoster virus latency, neurological disease and experimental models: an update.

Authors:  Randall J Cohrs; Donald H Gilden; Ravi Mahalingam
Journal:  Front Biosci       Date:  2004-01-01

Review 8.  The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

Authors:  Michael A Rogawski; Wolfgang Löscher
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

9.  Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.

Authors:  Tinna M Laughlin; Kevin V Tram; George L Wilcox; Angela K Birnbaum
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

10.  Painful neuropathy alters the effect of gabapentin on sensory neuron excitability in rats.

Authors:  A Kanai; C Sarantopoulos; J B McCallum; Q Hogan
Journal:  Acta Anaesthesiol Scand       Date:  2004-04       Impact factor: 2.105

View more
  9 in total

Review 1.  Postherpetic neuralgia #272.

Authors:  Shannon Ryan-Cebula; Hunter Groninger
Journal:  J Palliat Med       Date:  2013-08-15       Impact factor: 2.947

Review 2.  The role of sensory fiber demography in trigeminal and postherpetic neuralgias.

Authors:  A F DaSilva; M F DosSantos
Journal:  J Dent Res       Date:  2011-06-13       Impact factor: 6.116

3.  Relationship of axonal voltage-gated sodium channel 1.8 (NaV1.8) mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats.

Authors:  Supanigar Ruangsri; Audrey Lin; Yatendra Mulpuri; Kyung Lee; Igor Spigelman; Ichiro Nishimura
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

4.  Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models.

Authors:  Paul R Kinchington; William F Goins
Journal:  J Neurovirol       Date:  2011-12-28       Impact factor: 3.739

5.  Spinal astrocytic activation is involved in a virally-induced rat model of neuropathic pain.

Authors:  Gui-He Zhang; Miao-Miao Lv; Shuang Wang; Lei Chen; Nian-Song Qian; Yu Tang; Xu-Dong Zhang; Peng-Cheng Ren; Chang-Jun Gao; Xu-De Sun; Li-Xian Xu
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

Review 6.  Current gene therapy using viral vectors for chronic pain.

Authors:  Jean-Marc G Guedon; Shaogen Wu; Xuexing Zheng; Caroline C Churchill; Joseph C Glorioso; Ching-Hang Liu; Shue Liu; Lucy Vulchanova; Alex Bekker; Yuan-Xiang Tao; Paul R Kinchington; William F Goins; Carolyn A Fairbanks; Shuanglin Hao
Journal:  Mol Pain       Date:  2015-05-13       Impact factor: 3.395

7.  Effect of duloxetine premedication for postherpetic neuralgia within 72 h of herpes zoster reactivation [PROCESS]: a study protocol for a randomized controlled trial.

Authors:  Zheng Chen; Niti Shrestha; Chunmei Zhao; Bifa Fan; Fang Luo
Journal:  Trials       Date:  2020-12-09       Impact factor: 2.279

8.  A fixed nitrous oxide/oxygen mixture as an analgesic for patients with postherpetic neuralgia: study protocol for a randomized controlled trial.

Authors:  Hai-Xiang Gao; Jun-Jun Zhang; Ning Liu; Yi Wang; Chun-Xiang Ma; Lu-Lu Gao; Qiang Liu; Ting-Ting Zhang; Yi-Ling Wang; Wen-Qiang Bao; Yu-Xiang Li
Journal:  Trials       Date:  2021-01-06       Impact factor: 2.279

9.  Sex differences underlying orofacial varicella zoster associated pain in rats.

Authors:  Crystal Stinson; Mohong Deng; Michael B Yee; Larry L Bellinger; Paul R Kinchington; Phillip R Kramer
Journal:  BMC Neurol       Date:  2017-05-17       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.